Overview

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety,efficacy,pharmacokinetics and pharmacodynamics of multiple-dose of STSP-0601 at two dose levels for the treatment of bleeding episodes in hemophilia A or B patients without inhibitor.
Phase:
Phase 2
Details
Lead Sponsor:
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Collaborator:
Beijing Novikang Medical Technology Co., LTD